2022 (v1)
Journal article
No description
Uploaded on: December 3, 2022
C
J
Last name: CIRON
First name: J.
No description
Objective : As phase III trials have shown interest in innovative but expensive drugs in the treatment of neuromyelitis optica spectrum disorder (NMOSD), data are needed to clarify strategies in the treatment of neuromyelitis optica (NMO). This meta-analysis compares the efficacy of first-line strategies using rituximab (RTX), mycophenolate...